- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Progyny Stock Receives 'Moderate Buy' Rating from Analysts
Fertility benefits company Progyny sees mixed analyst recommendations as stock price declines.
Apr. 6, 2026 at 9:51am
Got story updates? Submit your updates here. ›
Progyny, Inc. (NASDAQ:PGNY), a fertility benefits management company, has received a consensus 'Moderate Buy' recommendation from 13 research firms covering the stock, according to MarketBeat.com. While four analysts have rated the stock as a 'hold', nine have assigned a 'buy' rating, with an average 12-month price target of $27.91.
Why it matters
Progyny's stock performance and analyst sentiment are closely watched as the company aims to disrupt the fertility benefits market by offering comprehensive, outcomes-focused coverage to employers and health plans. The mixed ratings reflect the challenges Progyny faces in a competitive landscape as it seeks to maintain its growth trajectory.
The details
Several equity analysts have recently issued reports on Progyny. Truist Financial decreased their price target on the stock from $34 to $28, while JPMorgan Chase & Co. set a $35 target price. BTIG Research dropped their price target from $35 to $30, and Weiss Ratings downgraded the stock from 'buy' to 'hold'.
- Progyny reported its Q4 2025 earnings on February 26, 2026.
- The company provided FY 2026 guidance and Q1 2026 guidance on the earnings call.
The players
Progyny, Inc.
A New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs.
Truist Financial
A financial services company that covers Progyny stock and recently decreased their price target.
JPMorgan Chase & Co.
A global financial services firm that covers Progyny and set a $35 price target on the stock.
BTIG Research
An equity research firm that covers Progyny and dropped their price target from $35 to $30.
Weiss Ratings
A financial research and ratings agency that downgraded Progyny from 'buy' to 'hold'.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee
The takeaway
Progyny's mixed analyst ratings reflect the challenges the company faces in the competitive fertility benefits market, as it seeks to maintain its growth momentum and market share. The stock's performance will be closely watched by investors as Progyny navigates this dynamic industry.
